Market Place
Sourcing Support
All News #Library
Biotech
Bright Minds Biosciences To Present At Upcoming Conferences
25 Feb 2026 //
GLOBENEWSWIRE
Bright Minds Bio Launches $100M Public Offering
06 Jan 2026 //
GLOBENEWSWIRE
Bright Minds Anti-Seizure Candidate Shines In Phase 2 Win
06 Jan 2026 //
GLOBENEWSWIRE
Bright Minds: BMB-101 Phase 2 Topline for Absence Epilepsy
05 Jan 2026 //
GLOBENEWSWIRE
Bright Minds Biosciences To Present At Piper Sandler Healthcare
25 Nov 2025 //
GLOBENEWSWIRE
Bright Minds Biosciences to Present at Upcoming Conferences
30 Oct 2025 //
GLOBENEWSWIRE
Bright Minds Biosciences to Present at Upcoming Conferences
25 Aug 2025 //
GLOBENEWSWIRE
Bright Minds Bio Reveals Speakers for Absence Epilepsy R&D Day
20 May 2025 //
GLOBENEWSWIRE
Bright Minds Reports Positive BMB-101 Results in Mouse Model
13 May 2025 //
GLOBENEWSWIRE
Bright Minds to Participate at 3 Healthcare Conferences in March
24 Feb 2025 //
GLOBENEWSWIRE
Bright Minds Bio Appoints Stephen as Chief Medical Officer
07 Jan 2025 //
GLOBENEWSWIRE
Bright Minds Bio And Firefly Neuro Collaborate On BMB-101 Analysis
21 Oct 2024 //
GLOBENEWSWIRE
Firefly Collaborates With Bright Minds On Ph 1 Data BNA™
16 Oct 2024 //
GLOBENEWSWIRE
Bright Minds Bio To Join Upcoming Science And Partner Events
03 Oct 2024 //
GLOBENEWSWIRE
Bright Minds Biosciences To Host Investor & Analyst Event
19 Sep 2024 //
GLOBENEWSWIRE
Bright Minds Initiates Phase 2 Trial Of BMB-101 In Epilepsy
12 Sep 2024 //
PR NEWSWIRE
Bright Minds Biosciences Announces Positive qEEG Data from Phase 1 Study BMB-101
08 Aug 2023 //
PRESS RELEASE
Bright Minds Announces Positive Topline Data for Phase 1 Study of BMB-101
20 Jul 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.